1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Leap Therapeutics, Inc.

Leap Therapeutics, Inc.

LPTX
Leap Therapeutics, Inc.US flagNASDAQ Global Market
0.77
USD
-0.02
- -
31.86MMarket Cap
Leap Therapeutics, Inc.
LPTX
(NASDAQ Global Market)

Recent

price

0.77

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
0.25
0.17
- -
- -
- -
- -
Revenue per Share
-4.8
-11.34
-21.45
-7.06
-27.29
-32.71
-16.36
-14.57
-6.28
-4.73
-4.82
-3.98
-1.8
-1.23
Basic EPS, GAAP
-4.75
-6.22
-15.38
-4.75
-27.13
-24.23
-18.41
-11.96
-4.38
-4.1
-4.33
-2.14
-1.61
-1.28
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-15.11
-26.45
-57.45
-41.26
-107.18
-142.31
-108.54
-86.41
-37.58
-30.7
-28.1
-19.54
-12.45
-12.16
Book Value per Share
7.25
11.11
38.72
-41.21
-106.71
12.13
6.49
-0.77
7.86
12.57
5.2
2.94
0.93
0.07
Tangible Book Value per Share
2
2
1
2
1
1
1
2
6
9
11
20
38
41
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
2
2
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
-1,887.2
-2,680
- -
- -
- -
- -
Operating Margin (%)
1
1
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-8
-18
-25
-12
-26
-30
-23
-33
-28
-41
-55
-81
-68
-51
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
-1,834.27
-2,705.8
- -
- -
- -
- -
Profit Margin (%)
15
18
44
-5
-32
22
11
-4
45
107
57
59
34
2
Working Capital
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
- -
- -
- -
- -
LT Debt
13
19
46
-70
-100
11
9
-2
47
108
59
60
35
3
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'25
Jun'25
Sep'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
41
41
41
Market Capitalization
12
12
19

Working Capital

FRC

•

in mil. unless spec.
Mar'25
Jun'25
Sep'25
Total Current Assets
34
19
10
Cash, Cash Equivalents & STI
33
18
10
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
14
14
9
Payables & Accruals
14
11
6
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-317.81%
-544.21%
-41.72%
Free Cash Flow
26.51%
19.62%
37.82%
Net Income, GAAP
19.38%
19.55%
-17.02%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-3.24
-0.91
-0.51
- -
-3.98
2024
-0.51
-0.51
-0.44
-0.37
-1.8
2025
-0.37
-0.4
-0.08
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Liminatus Pharma, Inc. Class A Common Stock (LIMN)
AEON Biopharma, Inc. (AEON)
Molecular Partners AG (MOLN)
Nxera Pharma Co., Ltd. (4565.T)
Enlivex Therapeutics Ltd. (ENLV.TA)
OSR Holdings, Inc. (OSRHW)
Business
Leap Therapeutics, Inc. (Nasdaq: LPTX) is a clinical-stage biopharmaceutical company that acquires, develops, and commercializes targeted antibody therapies for cancer patients; its lead product candidate, sirexatamab (DKN-01), comprises a humanized monoclonal antibody inhibiting Dickkopf-1 (DKK1) protein in advanced esophagogastric, gynecologic, endometrial, gastric, and colorectal cancers, including ongoing or completed trials combining sirexatamab with tislelizumab plus chemotherapy, bevacizumab plus chemotherapy, or pembrolizumab; FL-301 offers a humanized monoclonal antibody targeting Claudin18.2 for gastric and pancreatic cancers; and FL-501 provides a humanized monoclonal antibody inhibiting growth and differentiation factor 15 (GDF-15) protein in preclinical development. The company maintains license and option agreements with Adimab, LLC, and BeiGene, Ltd., for DKN-01 development and commercialization in Asia (excluding Japan), Australia, and New Zealand. Founded in 2011 and headquartered in Cambridge, Massachusetts, Leap Therapeutics operates primarily in the United States with a global clinical trial footprint targeting oncology patients expressing specific biomarkers. Recent developments include the July 2025 acquisition of Flame Biosciences for approximately $50 million in cash and stock to expand its Claudin18.2 pipeline with FL-301; a June 2025 strategic restructuring with 50-75% workforce reduction, positive Phase 2 DeFianCe trial data for sirexatamab in colorectal cancer, and exploration of alternatives such as partnerships or sales advised by Raymond James; and a $58.9 million private placement in October 2025 led by Winklevoss Capital to fund digital asset treasury initiatives, FL-501 advancement, and sirexatamab programs, alongside board expansion and Winklevoss nominees including a chair.

Company News

APIChat

  • defenseworld.net

    Leap Therapeutics (NASDAQ:LPTX) vs. Panbela Therapeutics (OTCMKTS:PBLA) Head-To-Head Analysis

  • defenseworld.net

    Leap Therapeutics (NASDAQ:LPTX) and Nemus Bioscience (OTCMKTS:NMUS) Critical Contrast

  • defenseworld.net

    Contrasting Leap Therapeutics (NASDAQ:LPTX) and UCB (OTCMKTS:UCBJF)

  • defenseworld.net

    Reviewing Leap Therapeutics (NASDAQ:LPTX) and Vincerx Pharma (NASDAQ:VINC)

  • defenseworld.net

    Analyzing PaxMedica (NASDAQ:PXMD) and Leap Therapeutics (NASDAQ:LPTX)

  • prnewswire.com

    Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results

  • prnewswire.com

    Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy

  • prnewswire.com

    Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025

  • prnewswire.com

    Leap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy

  • prnewswire.com

    Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy

  • prnewswire.com

    Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025

  • prnewswire.com

    Leap Therapeutics Reports Second Quarter 2025 Financial Results

  • prnewswire.com

    Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives

  • prnewswire.com

    Leap Therapeutics Reports First Quarter 2025 Financial Results

  • prnewswire.com

    Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting

  • prnewswire.com

    Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer

  • seekingalpha.com

    Leap Therapeutics (LPTX) Conference Call to discuss Updated Data from Part B of the DeFianCe Study Transcript

  • benzinga.com

    Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer

  • prnewswire.com

    Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

  • prnewswire.com

    Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study